



Navigating Gastrointestinal Challenges: Insight Into GERD and H. Pylori Management

REFERENCES

- Antunes C, Aleem A, Curtis SA. Gastroesophageal Reflux Disease(Archived). In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan—. PMID: 28722967. Updated July 3, 2023.
- Bandyopadhyay S, Verma P, Samajdar SS, Das S. Vonoprazan causes symptomatic improvement in non-erosive gastroesophageal reflux disease: A systematic review and meta-analysis. *Clin Res Hepatol Gastroenterol*. 2024;58(6):102373. doi:10.1016/j.clinre.2024.102373
- Cai JX, Campbell EJ, Richter JM. Concordance of outpatient esophagogastroduodenoscopy of the upper gastrointestinal tract with evidence-based guidelines. *JAMA Intern Med*. 2015;175(9):1563-1564. doi:10.1001/jamainternmed.2015.3533
- Chatila AT, Nguyen MTT, Krill T, Roark R, Bilal M, Reep G. Natural history, pathophysiology and evaluation of gastroesophageal reflux disease. *Dis Mon*. 2020;66(1):100848. doi:10.1016/j.disamonth.2019.02.001
- Chen JW, Vela MF, Peterson KA, Carlson DA. AGA clinical practice update on the diagnosis and management of extraesophageal gastroesophageal reflux disease: Expert review. *Clin Gastroenterol Hepatol*. 2023;21(6):1414-1421. doi:10.1016/j.cgh.2023.01.040
- Chey WD, Howden CW, Moss SF, et al. ACG Clinical Guideline: Treatment of Helicobacter pylori infection. *Am J Gastroenterol*. 2024;119(9):1730-1753. doi:10.14309/ajg.0000000000002968
- Correa P, Piazzuelo MB. Natural history of Helicobacter pylori infection. *Dig Liver Dis*. 2008;40(7):490-496. doi:10.1016/j.dld.2008.02.035
- Daniels B, Pearson SA, Buckley NA, Bruno C, Zoega H. Long-term use of proton-pump inhibitors: whole-of-population patterns in Australia 2013-2016. *Therap Adv Gastroenterol*. 2020;13:1756284820913743. doi:10.1177/1756284820913743
- Davis TA, Gyawali CP. Refractory gastroesophageal reflux disease: diagnosis and management. *J Neurogastroenterol Motil*. 2024;30(1):17-28. doi:10.5056/jnm23145
- Fass R, Vaezi M, Sharma P, et al. Randomised clinical trial: Efficacy and safety of on-demand vonoprazan versus placebo for non-erosive reflux disease. *Aliment Pharmacol Ther*. 2023;58(10):1016-1027. doi:10.1111/apt.17728
- Gyawali CP, Yadlapati R, Fass R, et al. Updates to the modern diagnosis of GERD: Lyon consensus 2.0. *Gut*. 2024;73(2):361-371. doi:10.1136/gutjnl-2023-330616
- Herregods TVK, Troelstra M, Weijenborg PW, Bredenoord AJ, Smout AJPM. Patients with refractory reflux symptoms often do not have GERD. *Neurogastroenterol Motil*. 2015;27(9):1267-1273. doi:10.1111/nmo.12620



Navigating Gastrointestinal Challenges: Insight Into GERD and H. Pylori Management

Hess MW, Hoenderop JG, Bindels RJ, Drenth JP. Systematic review: hypomagnesaemia induced by proton pump inhibition. *Aliment Pharmacol Ther.* 2012;36(5):405-413. doi:10.1111/j.1365-2036.2012.05201.x

Howden CW, Hunt RH. Guidelines for the management of Helicobacter pylori infection. *Am J Gastroenterol.* 1998;93(12):2330-2338. doi:10.1111/j.1572-0241.1998.00684

Jaynes M, Kumar AB. The risks of long-term use of proton pump inhibitors: a critical review. *Ther Adv Drug Saf.* 2019;10. doi:10.1177/2042098618809927

Kahrilas P, Yadlapati R, Roman S. Emerging dilemmas in the diagnosis and management of gastroesophageal reflux disease. *F1000Res.* 2017;6:1748. doi:10.12688/f1000research.11918.1

Kamal AN, Achalu S, Jani S, Triadafilopoulos G, Clarke JO, Wang CJ. Knowledge of patients' activation level changes expert US physicians' communication in GERD management. *J Clin Gastroenterol.* Published online 2024. doi:10.1097/MCG.0000000000002036

Katz PO, Dunbar K, Schnoll-Sussman FH, Greer KB, Spechler SJ. ACG Clinical Guideline: Guidelines for the diagnosis and management of gastroesophageal reflux disease. *Am J Gastroenterol.* 2022;117(1):27-56. doi:10.14309/ajg.0000000000001538

Kramer JR, Shakhathreh MH, Naik AD, et al. Use and yield of endoscopy in patients with uncomplicated gastroesophageal reflux disease. *JAMA Intern Med.* 2014;174(3):462-465. doi:10.1001/jamainternmed.2013.13015

Kubo A, Block G, Quesenberry CP, Buffler P, Corley DA. Dietary guideline adherence for gastroesophageal reflux disease. *BMC Gastroenterol.* 2014;14:144. doi:10.1186/1471-230X-14-144

Kwok CS, Arthur AK, Anibueze CI, Singh S, Cavallazzi R, Loke YK. Risk of Clostridium difficile infection with acid suppressing drugs and antibiotics: meta-analysis. *Am J Gastroenterol.* 2012;107(7):1011-1019. doi:10.1038/ajg.2012.108

Labenz J, Menzel M, Hirsch O, Muller M, Labenz C, Adarkwah CC. Symptoms, the GerdQ score, and patients' characteristics do not predict gastroesophageal reflux disease in patients with proton-pump inhibitor-refractory reflux symptoms – results from a large prospective database. *PeerJ.* 2023;11:e14802. doi:10.7717/peerj.14802

Laine L, DeVault K, Katz P, et al. Vonoprazan versus lansoprazole for healing and maintenance of healing of erosive esophagitis: a randomized trial. *Gastroenterology.* 2023;164(1):61-71. doi:10.1053/j.gastro.2022.09.041

Laine L, Spechler S, Yadlapati R, et al. Vonoprazan is efficacious for treatment of heartburn in non-erosive reflux disease: A randomized trial. *Clin Gastroenterol Hepatol.* Published online 2024. doi:10.1016/j.cgh.2024.05.004



Navigating Gastrointestinal Challenges: Insight Into GERD and H. Pylori Management

Lehault WB, Hughes DM. Review of the long-term effects of proton pump inhibitors. *Fed Pract.* 2017;34(2):19-23.

Malfertheiner P, Camargo MC, El-Omar E, et al. Helicobacter pylori infection. *Nat Rev Dis Primers.* 2023;9(1):19. doi:10.1038/s41572-023-00431-8

Mégraud F, Graham DY, Howden CW, et al. Rates of antimicrobial resistance in Helicobacter pylori isolates from clinical trial patients across the US and Europe. *Am J Gastroenterol.* 2023;118(2):269-275. doi:10.14309/ajg.0000000000002045

Modlin IM, Hunt RH, Malfertheiner P, et al. Diagnosis and management of non-erosive reflux disease – the Vevy NERD consensus group. *Digestion.* 2009;80(2):74-88. doi:10.1159/000219365

Nehra AK, Alexander JA, Loftus CG, Nehra V. Proton Pump inhibitors: Review of emerging concerns. *Mayo Clin Proc.* 2018;93(2):240-246. doi:10.1016/j.mayocp.2017.10.022

Nirwan JS, Hasan SS, Babar ZUD, Conway BR, Ghori MU. Global prevalence and risk factors of gastro-oesophageal reflux disease (GORD): Systematic review with meta-analysis. *Sci Rep.* 2020;10(1):5814. doi:10.1038/s41598-020-62795-1

Rawla P, Sunkara T, Ofosu A, Gaduputi V. Potassium-competitive acid blockers – are they the next generation of proton pump inhibitors? *World J Gastrointest Pharmacol Ther.* 2018;9(7):63-68. doi:10.4292/wjgpt.v9.i7.63

Rubenstein JH, Jiang L, Kurlander JE, et al. Incomplete response of gastroesophageal reflux symptoms poorly predicts erosive esophagitis or Barrett's esophagus. *Clin Gastroenterol Hepatol.* 2021;19:2284-2292. doi:10.1016/j.cgh.2020.08.044

Savarino E, de Bortoli N, De Cassan C, et al. The natural history of gastro-esophageal reflux disease: a comprehensive review. *Dis Esophagus.* 2017;30(2):1-9. doi:10.1111/dote.12511

Shao Y, Lin Y, Fang Z, Yan J, Zheng T, Ye G. Analysis of *Helicobacter pylori* resistance in patients with different gastric diseases. *Sci Rep.* 2024;14:4912. doi:10.1038/s41598-024-55589-2

Simadibrata DM, Syam AF, Lee YY. A comparison of efficacy and safety of potassium-competitive acid blocker and proton pump inhibitor in gastric acid-related diseases: A systematic review and meta-analysis. *J Gastroenterol Hepatol.* 2022;37(12):2217-2228. doi:10.1111/jgh.16017

Thabet R, Hussain AA, Gupta S, Anand C. Adherence to 2013 guidelines for proton pump inhibitor weaning in GERD. *Am J Gastroenterol.* 2015;110:S1036-S1037.

Thurber KM, Otto AO, Stricker SL. Proton pump inhibitors: Understanding the associated risks and benefits of long-term use. *Am J Health Syst Pharm.* 2023;80(8):487-494. doi:10.1093/ajhp/zxad009

Vaezi MF. Atypical manifestations of gastroesophageal reflux disease. *Med Gen Med.* 2005;7(4):25.



Navigating Gastrointestinal Challenges: Insight Into GERD and H. Pylori Management

Wiklund I. Review of the quality of life and burden of illness in gastroesophageal reflux disease. *Dig Dis*. 2004;22(2):108-114. doi:10.1159/000080308

Wong N, Reddy A, Patel A. Potassium-competitive acid blockers: present and potential utility in the armamentarium for acid peptic disorders. *Gastroenterol Hepatol (NY)*. 2022;18(12):693-700.

Wu DC, Wu IC, Wang SW, et al. Comparison of stool enzyme immunoassay and immunochromatographic method for detecting *Helicobacter pylori* antigens before and after eradication. *Diagn Microbiol Infect Dis*. 2006;56(4):373-378. doi:[10.1016/j.diagmicrobio.2006.07.006](https://doi.org/10.1016/j.diagmicrobio.2006.07.006)

Yadlapati R, Cappell K, Sedgley R, et al. A linked electronic medical record-claims analysis of the clinical and economic outcomes of patients coded for erosive esophagitis in the United States. *Adv Ther*. 2023;40(12):5489-5501. doi:10.1007/s12325-023-02688-7

Yadlapati R, Gyawali CP, Pandolfino JE, et al. AGA clinical practice update on the personalized approach to the evaluation and management of GERD: Expert Review. *Clin Gastroenterol Hepatol*. 2022;20(5):984-994. doi:10.1016/j.cgh.2022.01.025